150 related articles for article (PubMed ID: 38261000)
21. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma.
Gong Y; Song L; Ou L; Lu YY; Huang X; Zeng Q
Iran J Med Sci; 2023 Jul; 48(4):401-413. PubMed ID: 37456201
[TBL] [Abstract][Full Text] [Related]
23. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer.
Yu Y; Tong Y; Zhong A; Wang Y; Lu R; Guo L
Medicine (Baltimore); 2020 Dec; 99(52):e23863. PubMed ID: 33350781
[TBL] [Abstract][Full Text] [Related]
24. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
Joergensen MT; Brünner N; De Muckadell OB
Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
[TBL] [Abstract][Full Text] [Related]
25. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
26. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
[TBL] [Abstract][Full Text] [Related]
27. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers.
Boyd LNC; Ali M; Comandatore A; Garajova I; Kam L; Puik JR; Fraga Rodrigues SM; Meijer LL; Le Large TYS; Besselink MG; Morelli L; Frampton A; van Laarhoven HWM; Giovannetti E; Kazemier G
JAMA Netw Open; 2023 Aug; 6(8):e2331197. PubMed ID: 37639271
[TBL] [Abstract][Full Text] [Related]
28. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
[TBL] [Abstract][Full Text] [Related]
29. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract][Full Text] [Related]
31. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic Cancer Insights: Optimization of the Diagnostic Capacity of Tumor Biomarkers.
Delgado JA; Ballesteros MA; Parera MM; Bauça JM
Lab Med; 2021 Nov; 52(6):550-557. PubMed ID: 33900408
[TBL] [Abstract][Full Text] [Related]
33. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
34. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
[TBL] [Abstract][Full Text] [Related]
35. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
36. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
[TBL] [Abstract][Full Text] [Related]
37. Circulating natural antibodies against 3'-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma.
Yamada K; Higashi K; Nagahori H; Saito K
Cancer Biomark; 2020; 27(1):121-128. PubMed ID: 31771041
[TBL] [Abstract][Full Text] [Related]
38. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.
Le Large TYS; Meijer LL; Paleckyte R; Boyd LNC; Kok B; Wurdinger T; Schelfhorst T; Piersma SR; Pham TV; van Grieken NCT; Zonderhuis BM; Daams F; van Laarhoven HWM; Bijlsma MF; Jimenez CR; Giovannetti E; Kazemier G
Oncologist; 2020 Apr; 25(4):e634-e643. PubMed ID: 31943574
[TBL] [Abstract][Full Text] [Related]
39. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
40. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]